TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2121848

Group type: EXPERIMENTAL
Intervention: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 6-monthly full dose)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by 3-monthly half doses)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Prolonged praziquantel courses (initial dose of 40 mg/Kg, followed by monthly half doses)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oral vitamin B complex (placebo)
Number of subjects: 6
Study: 4577030

Group type: EXPERIMENTAL
Intervention: Uriglox chemical test
Number of subjects: 351
Study: 30942613

Group type: EXPERIMENTAL
Intervention: 2 Hz TEAS (n=31)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Mock stimulation (n=29)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control group (lifestyle advice only, n=30)
Number of subjects: 121
Study: 27207372

Group type: EXPERIMENTAL
Intervention: PAX good behavior game (PAX GBG)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Integration of PAX GBG and PATHS
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 27
Study: 25598168

Group type: EXPERIMENTAL
Intervention: Exercise plus Restwise
Number of subjects: 50

Group type: COMPARATOR
Intervention: Exercise only
Number of subjects: 50
Study: 23570248

Group type: EXPERIMENTAL
Intervention: Clarithromycin (7.5 mg/kg/dose every 12 hours)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21993028

Group type: EXPERIMENTAL
Intervention: 2 depth jumps from a height of 33 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 4 depth jumps from a height of 33 cm
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: 6 depth jumps from a height of 33 cm
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control condition (no depth jumps)
Number of subjects: 14
Study: 19362003

Group type: EXPERIMENTAL
Intervention: Hyaluronan (Ostenil)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Triamcinolone (Volon A10)
Number of subjects: 35
Study: 16928473

Group type: EXPERIMENTAL
Intervention: Wines fined with egg white, isinglass, or non-grape-derived tannins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Milk protein-fined wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (unfined wine)
Number of subjects: 0
Study: 15201240

Group type: EXPERIMENTAL
Intervention: Troponin T testing
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Continuous ST segment monitoring
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Composite end point (cardiac death and acute myocardial infarction)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Age >= 65 years, diabetes, previous myocardial infarction, congestive heart failure, use of beta blockers or diuretics at admission, 12 lead ECG ST segment depression at admission, troponin T concentration >= 0.10 microg/l, and >= 1 ST vector magnitude episodes
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Age >= 65 years, previous myocardial infarction, and troponin T concentration >= 0.10 microg/l
Number of subjects: 213
Study: 10675582

Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 9350559

Group type: EXPERIMENTAL
Intervention: Resorbable barrier (Resolut Regenerative Material)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Non-resorbable barrier (Gore-Tex Periodontal Material)
Number of subjects: 12
Study: 8457776

Group type: EXPERIMENTAL
Intervention: GM-CSF after AuBMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 2878175

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion
Number of subjects: 36

Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Insulin infusion
Number of subjects: 36
Study: 31478164

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 100
Study: 29356462

Group type: EXPERIMENTAL
Intervention: Intravenous drip of 99 Tc-MDP
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination treatment of intravenous drip of 99 Tc-MDP and oral meloxicam tablets
Number of subjects: 120

Group type: COMPARATOR
Intervention: Oral meloxicam tablets
Number of subjects: 120
Study: 27388600

Group type: EXPERIMENTAL
Intervention: Brief, multi-component gatekeeper intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 106
Study: 25294786

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 22758783

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (ECV)
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Previous ECV
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Left atrium enlargement
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: AF duration >6 months at time of procedure
Number of subjects: 521
Study: 19804441

Group type: EXPERIMENTAL
Intervention: Low dose fluticasone 100 microg/day with intranasal placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High dose fluticasone 500 microg/day with intranasal placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined fluticasone 100 microg/day with intranasal fluticasone 200 microg/day
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 25

Group type: COMPARATOR
Intervention: High dose fluticasone vs Low dose fluticasone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Combined vs Low dose fluticasone
Number of subjects: 25
Study: 18559634

Group type: EXPERIMENTAL
Intervention: Facilitatory insole
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional insole
Number of subjects: 40
Study: 15847950

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 23

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day
Number of subjects: 23
Study: 12416538

Group type: EXPERIMENTAL
Intervention: Upper removable appliance (URA)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Jones Jig
Number of subjects: 23
Study: 10715760

Group type: EXPERIMENTAL
Intervention: Acute stroke group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 8538891

Group type: EXPERIMENTAL
Intervention: Verbal medication counseling from a pharmacist
Number of subjects: 70

Group type: COMPARATOR
Intervention: No verbal medication counseling (uncounseled)
Number of subjects: 70
Study: 1837743

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6) plus Dexamethasone (20 mg IV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ondansetron (8 mg IV before cisplatin, then 1 mg/h for 24 hours; oral 8 mg three times daily on days 2-6)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combination treatment (Ondansetron + Dexamethasone)
Number of subjects: 100
Study: 7150458

Group type: EXPERIMENTAL
Intervention: C 49802 B‐Ba
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CGP 12103/A
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31990967

Group type: EXPERIMENTAL
Intervention: HERO Wellness Scale
Number of subjects: 84

Group type: COMPARATOR
Intervention: WHO‐5 Well‐Being Index
Number of subjects: 84
Study: 31311668

Group type: EXPERIMENTAL
Intervention: Temelimab at doses of 36, 60, 85, and 110 mg/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 28937446

Group type: EXPERIMENTAL
Intervention: Robotic-assisted laparoscopy
Number of subjects: 101

Group type: COMPARATOR
Intervention: Traditional laparoscopy
Number of subjects: 101
Study: 24449558

Group type: EXPERIMENTAL
Intervention: Invisible social support
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Non-confounded visible social support
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Visible social support (as delivered in a 2007 study by Bolger and Amarel)
Number of subjects: 73

Group type: COMPARATOR
Intervention: No social support
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control and replication conditions
Number of subjects: 73
Study: 24171301

Group type: EXPERIMENTAL
Intervention: Topical ivermectin (1% applied at 400 microg/kg, repeated once the following week)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Permethrin 2.5% cream (applied twice at one week intervals)
Number of subjects: 380
Study: 21733058

Group type: EXPERIMENTAL
Intervention: Alogliptin 25 mg (Alo25) added to Metformin and Pioglitazone
Number of subjects: 803

Group type: COMPARATOR
Intervention: Pioglitazone 15 mg (Met+Pio45)
Number of subjects: 803
Study: 19318791

Group type: EXPERIMENTAL
Intervention: Online course of instruction
Number of subjects: 16

Group type: COMPARATOR
Intervention: Face-to-face course of instruction
Number of subjects: 16
Study: 16400465

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (10 mg/kg loading dose before incision, followed by 1 mg/kg/h for 5 hours)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (normal saline bolus and continuous infusion for 5 hours)
Number of subjects: 65
Study: 15262026

Group type: EXPERIMENTAL
Intervention: Sedation with midazolam elixir
Number of subjects: 18

Group type: COMPARATOR
Intervention: Analgesia with morphine sulphate
Number of subjects: 18

Group type: COMPARATOR
Intervention: Combination therapy with dextromoramide and lorazepam
Number of subjects: 18
Study: 11706519

Group type: EXPERIMENTAL
Intervention: Management strategies for bloodstream infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravascular catheters
Number of subjects: 0
Study: 9250038

Group type: EXPERIMENTAL
Intervention: Routine nursing care combined with eggcrate foam (n=20)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Routine nursing care combined with hydrocolloid dressing (n=15)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine nursing care alone (n=15)
Number of subjects: 50
Study: 8103382

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2935644

Group type: EXPERIMENTAL
Intervention: 1 mg diethylstilbestrol orally 3 times daily
Number of subjects: 465

Group type: COMPARATOR
Intervention: 250 mg oral cyproterone acetate daily
Number of subjects: 465

Group type: COMPARATOR
Intervention: 500 mg medroxyprogesterone acetate intramuscularly 3 times weekly for 8 weeks, then 200 mg orally daily
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 3 mg diethylstilbestrol
Number of subjects: 465

Group type: COMPARATOR
Intervention: 560 mg estramustine phosphate orally for 8 weeks, then 280 mg daily
Number of subjects: 465
Study: 30041701

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POM) supplementation, 50 ml daily for two months
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (POM) supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19

Group type: COMPARATOR
Intervention: Both groups (POM and placebo)
Number of subjects: 19
Study: 27029363

Group type: EXPERIMENTAL
Intervention: High exposed group (average concentration of cadmium >0.40 mg/kg in rice and >1.0 mg/kg in soil)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Low exposed group (average concentration of cadmium 0.15-0.40 mg/kg in rice and 0.5-1.0 mg/kg in soil)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Overall population (both groups)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Vegetable samples
Number of subjects: 414
Study: 25398670

Group type: EXPERIMENTAL
Intervention: CC genotype of rs324148
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CC genotype of rs9394992
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Adverse karyotypes
Number of subjects: 100
Study: 23387950

Group type: EXPERIMENTAL
Intervention: Community-based peer intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control city (no intervention)
Number of subjects: 200
Study: 20492853

Group type: EXPERIMENTAL
Intervention: Higher-dose paliperidone ER (12 mg/d)
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Lower-dose paliperidone ER (6 mg/d)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Paliperidone ER (both doses)
Number of subjects: 316
Study: 18954708

Group type: EXPERIMENTAL
Intervention: Calcifications as surrogates for prostate position during CBCT image-guided radiotherapy
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Low-dose CBCT imaging
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Standard CBCT imaging
Number of subjects: 131
Study: 15992986

Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic (RLB) waveform (120, 150, 200J)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) waveform (200, 300, 360J)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Rectilinear biphasic (RLB) waveform
Number of subjects: 169

Group type: COMPARATOR
Intervention: Monophasic damped sine (MDS) waveform
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Bystander witnessed events (RLB)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Bystander witnessed events (MDS)
Number of subjects: 169
Study: 12953145

Group type: EXPERIMENTAL
Intervention: Supervised training (S)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Self-monitored training (SM)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Maintenance program (MP)
Number of subjects: 39
Study: 11060418

Group type: EXPERIMENTAL
Intervention: Nadroparin (low molecular weight heparin)
Number of subjects: 24497

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 24497

Group type: COMPARATOR
Intervention: Low risk (no prevention)
Number of subjects: 24497
Study: 8800307

Group type: EXPERIMENTAL
Intervention: Cadexomer iodine ointment (Iodosorb)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard treatment (gentamicin solution, streptodornase/streptokinase, or dry saline gauze)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 25
Study: 1320306

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (720 EIU, 3 doses, 0, 1 month schedule, booster at month 6)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (3 consecutive lots)
Number of subjects: 204
Study: 6480953

Group type: EXPERIMENTAL
Intervention: Doxepin (10 mg three times daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cyproheptadine (4 mg three times daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hydroxyzine (10 mg three times daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Cinnarizine (10 mg three times daily)
Number of subjects: 9
Study: 31226579

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) technology for momentary assessments of persecutory ideation (PI)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Mobile health (mHealth) technology for momentary assessments of PI
Number of subjects: 62
Study: 29769060

Group type: EXPERIMENTAL
Intervention: Biodegradable inflatable balloon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 26973262

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for 8 weeks in addition to routine postoperative treatment
Number of subjects: 75

Group type: COMPARATOR
Intervention: Routine postoperative treatment only (Control)
Number of subjects: 75
Study: 25325925

Group type: EXPERIMENTAL
Intervention: Bemfola pen (BP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Puregon pen (PP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gonal-f pen (GP)
Number of subjects: 0
Study: 22773286

Group type: EXPERIMENTAL
Intervention: Antenatal treatment of maternal periodontitis
Number of subjects: 331

Group type: COMPARATOR
Intervention: Postpartum treatment of maternal periodontitis
Number of subjects: 331
Study: 19852869

Group type: COMPARATOR
Intervention: Distortion product otoacoustic emissions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Transient evoked otoacoustic emissions
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pure tone audiometry
Number of subjects: 26
Study: 17978257

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery program
Number of subjects: 210

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 210
Study: 17176801

Group type: EXPERIMENTAL
Intervention: Nasal cytology using the Rhinoprobe method
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (nonatopic children)
Number of subjects: 90
Study: 11894031

Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (OCA)
Number of subjects: 814

Group type: COMPARATOR
Intervention: Standard wound closure methods (SWC)
Number of subjects: 814
Study: 9867068

Group type: EXPERIMENTAL
Intervention: Perindopril (PE)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 45
Study: 8595687

Group type: EXPERIMENTAL
Intervention: Removal of the laryngeal mask airway by anaesthetist in deeply anaesthetised patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Removal of the laryngeal mask airway by nurse in awake patients
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (anaesthetised patients)
Number of subjects: 100
Study: 2774262

Group type: EXPERIMENTAL
Intervention: 5% glucose solution
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ringer's solution
Number of subjects: 20
Study: 31538810

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 24 h
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 48 h
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Low MAp19 levels at admission
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: MAp19 levels at 24-72 h
Number of subjects: 240

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 240
Study: 31495577

Group type: EXPERIMENTAL
Intervention: ROP position + pacifier (experimental group, n=35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Pacifier only (control group, n=35)
Number of subjects: 70
Study: 29019927

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (high MDS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (high MDS) among subjects with high Genetic Risk Score (GRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mediterranean Diet adherence (low GRS)
Number of subjects: 0
Study: 25927870

Group type: EXPERIMENTAL
Intervention: Usual care plus additional Saturday rehabilitation
Number of subjects: 996

Group type: COMPARATOR
Intervention: Usual care rehabilitation services from Monday to Friday
Number of subjects: 996
Study: 23020608

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 217

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 217
Study: 21733413

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care program from a clinical pharmacist
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care from medical and nursing staff
Number of subjects: 200
Study: 19663109

Group type: EXPERIMENTAL
Intervention: Ablative fractional photothermolysis (AFP)
Number of subjects: 10
Study: 16675610

Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mug once daily for 7-10 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 15798822

Group type: EXPERIMENTAL
Intervention: OptiBond SOLO
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Amalgambond Plus
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Etch & Prime 3.0
Number of subjects: 60
Study: 12001701

Group type: EXPERIMENTAL
Intervention: Immunoablative therapy including high dose cytotoxic agents and hematopoietic autologous stem‐cell rescue
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non‐myeloablative allogeneic transplantation and sub‐myeloblative high dose cyclophosphamide without stem cell support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study: 9572809

Group type: EXPERIMENTAL
Intervention: Sucrose solution (0.75 g/kg body wt)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Water
Number of subjects: 8
Study: 8586807

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (250 mg by intravenous infusion for 5 min)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 2768617

Group type: EXPERIMENTAL
Intervention: Videotaped coping model and film distraction technique
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 11
Study: 779796

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (average dose: 1.8 mg/kg/day)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide after crossover
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Number of subjects: 24
Study: 31860942

Group type: EXPERIMENTAL
Intervention: Primary closure of amputation stump
Number of subjects: 56

Group type: COMPARATOR
Intervention: Delayed primary closure of amputation stump
Number of subjects: 56
Study: 27842926

Group type: EXPERIMENTAL
Intervention: Nutritional supplementation via feeding jejunostomy (600 kcal/day)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No jejunal supplement (Control)
Number of subjects: 44
Study: 26329976

Group type: COMPARATOR
Intervention: Normal liver (F0)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Fibrosis without cirrhosis (F1–3)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Cirrhosis (F4)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: All groups (normal, fibrotic, cirrhotic)
Number of subjects: 215
Study: 23329881

Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy+rh‐endostatin
Number of subjects: 70
Study: 21628084

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) injection
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 19467028

Group type: EXPERIMENTAL
Intervention: Copper oxide containing pillowcases (0.4% weight/weight)
Number of subjects: 57